Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
2(20%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_3
4
40%
Ph phase_1
3
30%
Ph phase_2
3
30%

Phase Distribution

3

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
4(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(5)
Other(3)

Detailed Status

Completed5
Suspended2
unknown1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 23 (30.0%)
Phase 34 (40.0%)

Trials by Status

completed550%
suspended220%
unknown110%
recruiting110%
active_not_recruiting110%

Recent Activity

2 active trials
Showing 5 of 10
recruitingphase_1

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

NCT07182565
completedphase_2

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

NCT04172402
active_not_recruitingphase_1

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

NCT03252808
completedphase_2

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

NCT03382600
completedphase_3

Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer

NCT00498225
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07182565Phase 1

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT04172402Phase 2

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

Completed
NCT03252808Phase 1

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Active Not Recruiting
NCT03382600Phase 2

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

Completed
NCT00498225Phase 3

Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer

Completed
NCT00150670Phase 3

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Completed
NCT00209729Phase 1

Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.

Suspended
NCT00195572Phase 3

Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

Completed
NCT00316745Phase 3

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Suspended
NCT00209651Phase 2

Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10